Michael Wagner

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Thomas Berg, Michael Wagner, Samer Nasser et al. · Gastroenterology · 2006 · 519 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

Michael Wagner, M Huber, Thomas Berg et al. · Gastroenterology · 2005 · 455 citations

Medicine, Infectious Diseases, Pharmacotherapy +14

Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure

Alexander Nickel, Albrecht von Hardenberg, Mathias Hohl et al. · Cell Metabolism · 2015 · 374 citations · Full text

Life Sciences, Cardiology, Physiology +14

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

Christian M. Lange, Jörg Bojunga, Elizabeth Ramos‐Lopez et al. · Journal of Hepatology · 2010 · 243 citations · Full text

Medicine, Genetics, Molecular Genetics +13

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

Martin Lagging, Ana I. Romero, Johan Westin et al. · Hepatology · 2006 · 213 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17